Alnylam to Disclose Two Additional Drug Programs by Year-End

"We have about four or five different discovery programs right now that are in an intense bake-off," said CEO John Maraganore.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories